CORRECTED-Data and analytics firm Health Catalyst's Q4 revenue fell

Reuters03-13
CORRECTED-Data and analytics firm <a href="https://laohu8.com/S/HCAT">Health Catalyst</a>'s Q4 revenue fell

Corrects KD table to show revenue and gross margin figures are company-wide results, not technology-sector figures

Overview

  • U.S. healthcare analytics firm's Q4 revenue fell 6% yr/yr

  • Q4 adjusted EBITDA rose sharply and beat analyst expectations

  • Company posted large net loss due to goodwill and intangible asset impairments

Outlook

  • Health Catalyst expects Q1 2026 revenue between $68 mln and $70 mln

  • Company sees Q1 2026 Adjusted EBITDA between $7 mln and $8 mln

  • Company is not providing full-year 2026 guidance due to ongoing internal review and CEO transition

Result Drivers

  • IMPAIRMENT CHARGES - Co said net loss was driven by impairment of goodwill and intangible assets following impairment indicators and quantitative tests

  • COST REDUCTIONS - Gross margin improved due to lower costs, especially in professional services

  • CLIENT RETENTION - Dollar-based retention rate fell to 93% from 102%, indicating reduced client spend or attrition

Company press release: ID:nGNX4tHzSS

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

$74.68 mln

Q4 Net Income

-$91.03 mln

Q4 Adjusted EBITDA

Beat

$13.79 mln

$13.18 mln (10 Analysts)

Q4 Adj. Gross Margin

53.5%

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the software peer group is "buy"

  • Wall Street's median 12-month price target for Health Catalyst Inc is $3.88, about 108.3% above its March 11 closing price of $1.86

  • The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment